
    
      A multicenter, randomized, double-blind trial of brexpiprazole versus placebo for the acute
      treatment of manic episodes, with or without mixed features, associated with bipolar I
      disorder. This study also demonstrated the safety and tolerability of brexpiprazole in the
      study population of males and females aged 18 to 65 years (inclusive, at time of consent).
    
  